Surrogate Endpoints in Aids Drug Development: Current Status
- 1 April 1998
- journal article
- other
- Published by Springer Nature in Drug Information Journal
- Vol. 32 (2) , 439-448
- https://doi.org/10.1177/009286159803200215
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trialThe Lancet, 1997
- Decay characteristics of HIV-1-infected compartments during combination therapyNature, 1997
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Surrogate Endpoints in Clinical TrialsDrug Information Journal, 1996
- Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDSNew England Journal of Medicine, 1996
- Effect of the Antiarrhythmic Agent Moricizine on Survival after Myocardial InfarctionNew England Journal of Medicine, 1992
- Statistical validation of intermediate endpoints for chronic diseasesStatistics in Medicine, 1992
- Effect of Oral Milrinone on Mortality in Severe Chronic Heart FailureNew England Journal of Medicine, 1991
- Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or PlaceboNew England Journal of Medicine, 1991
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989